"Janus Kinase 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A Janus kinase subtype that is involved in signaling from a broad variety of CYTOKINE RECEPTORS.
| Descriptor ID |
D053613
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.124.100 D12.776.476.393.100
|
| Concept/Terms |
Janus Kinase 1- Janus Kinase 1
- JAK-1 Protein Tyrosine Kinase
- JAK 1 Protein Tyrosine Kinase
- JAK1 Protein Tyrosine Kinase
- Jak1 Kinase
|
Below are MeSH descriptors whose meaning is more general than "Janus Kinase 1".
Below are MeSH descriptors whose meaning is more specific than "Janus Kinase 1".
This graph shows the total number of publications written about "Janus Kinase 1" by people in this website by year, and whether "Janus Kinase 1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 3 | 6 | 9 |
| 2018 | 0 | 5 | 5 |
| 2019 | 1 | 2 | 3 |
| 2020 | 3 | 2 | 5 |
| 2021 | 2 | 3 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Janus Kinase 1" by people in Profiles.
-
SARS-CoV-2 Disrupts Proximal Elements in the JAK-STAT Pathway. J Virol. 2021 09 09; 95(19):e0086221.
-
Repurposing Methotrexate in Dampening SARS-CoV2-S1-Mediated IL6 Expression: Lessons Learnt from Lung Cancer. Inflammation. 2022 Feb; 45(1):172-179.
-
SARS-CoV-2 Spike protein enhances ACE2 expression via facilitating Interferon effects in bronchial epithelium. Immunol Lett. 2021 09; 237:33-41.
-
Understanding the Potential Role of Abrocitinib in the Time of SARS-CoV-2. J Drugs Dermatol. 2021 Jul 01; 20(7):806.
-
Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy. J Hepatol. 2021 09; 75(3):647-658.
-
COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon. Cytokine Growth Factor Rev. 2021 Aug; 60:28-45.
-
SARS-CoV-2 drives JAK1/2-dependent local complement hyperactivation. Sci Immunol. 2021 04 07; 6(58).
-
Pharmacological mechanism of immunomodulatory agents for the treatment of severe cases of COVID-19 infection. Inflamm Res. 2021 Apr; 70(4):389-405.
-
Perspectives on Targeting IL-6 as a Potential Therapeutic Strategy for COVID-19. J Interferon Cytokine Res. 2021 02; 41(2):37-43.
-
JAK1 Inhibition Blocks Lethal Immune Hypersensitivity in a Mouse Model of Down Syndrome. Cell Rep. 2020 11 17; 33(7):108407.